Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Expenses: 2016-2024

Historic Operating Expenses for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to $339.9 million.

  • Crinetics Pharmaceuticals' Operating Expenses rose 62.57% to $142.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $479.4 million, marking a year-over-year increase of 55.74%. This contributed to the annual value of $339.9 million for FY2024, which is 49.98% up from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Operating Expenses is $339.9 million, which was up 49.98% from $226.6 million recorded in FY2023.
  • In the past 5 years, Crinetics Pharmaceuticals' Operating Expenses registered a high of $339.9 million during FY2024, and its lowest value of $75.0 million during FY2020.
  • In the last 3 years, Crinetics Pharmaceuticals' Operating Expenses had a median value of $226.6 million in 2023 and averaged $246.4 million.
  • Data for Crinetics Pharmaceuticals' Operating Expenses shows a peak YoY soared of 58.69% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Operating Expenses stood at $75.0 million in 2020, then surged by 44.99% to $108.8 million in 2021, then soared by 58.69% to $172.6 million in 2022, then surged by 31.28% to $226.6 million in 2023, then skyrocketed by 49.98% to $339.9 million in 2024.